{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-12T06:39:01.968566+00:00","company":{"ticker":"CBIO","cik":1253689,"company_name":"CRESCENT BIOPHARMA, INC."},"pagination":{"limit":100,"returned":52,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","detail":"license","count":2,"first_seen":"2025-12-04T23:59:59+00:00","last_seen":"2025-12-04T23:59:59+00:00","evidence_fact_ids":[142572,142573]},{"display_name":"ARE-Maryland No. 45, LLC","detail":"lease","count":1,"first_seen":"2023-04-21T23:59:59+00:00","last_seen":"2023-04-21T23:59:59+00:00","evidence_fact_ids":[164307]},{"display_name":"Paragon Therapeutics, Inc.","detail":"license","count":1,"first_seen":"2025-12-04T23:59:59+00:00","last_seen":"2025-12-04T23:59:59+00:00","evidence_fact_ids":[142574]},{"display_name":"Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific","detail":"supply","count":1,"first_seen":"2024-01-02T23:59:59+00:00","last_seen":"2024-01-02T23:59:59+00:00","evidence_fact_ids":[84344]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"515c71f7e4bedffc5e90540f5eb0657d23eb0311","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-06-03T13:02:51+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"2,403,515","subject":null,"votes_abstain":"521","votes_against":null,"votes_for":null,"votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 4 - Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. 1 YEAR 2 YEARS 3 YEARS Votes ABSTAINED Broker Non-Votes 18,644,881 903 887 521 2,403,515","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-040051","anchor_url":"https://secwatch.observer/filing/0001628280-26-040051#claim-515c71f7e4bedffc5e90540f5eb0657d23eb0311","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8749948e009eabb79d53397d0a0648a15955dde3","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-06-03T13:02:51+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,403,515","subject":null,"votes_abstain":"876","votes_against":"300,217","votes_for":"18,346,099","votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 18,346,099 300,217 876 2,403,515","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-040051","anchor_url":"https://secwatch.observer/filing/0001628280-26-040051#claim-8749948e009eabb79d53397d0a0648a15955dde3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2f6fae34dc17a8f83e2932703079774577fba621","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-06-03T13:02:51+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"154","votes_against":"1,452","votes_for":"21,049,101","votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,049,101 1,452 154 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-040051","anchor_url":"https://secwatch.observer/filing/0001628280-26-040051#claim-2f6fae34dc17a8f83e2932703079774577fba621","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9b7e850d3c34bc9636d45a9d51b77e475410c174","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-06-03T13:02:51+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Election of two Class II directors to serve until the Company's 2029 Annual General Meeting of Shareholders","proposal_type":"director_election","results":[{"broker_non_votes":"0","subject":"Jonathan Violin, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"2,890,000","votes_withheld":"0"},{"broker_non_votes":"2,403,515","subject":"Susan Moran, M.D., MSCE","votes_abstain":null,"votes_against":null,"votes_for":"21,401,136","votes_withheld":"136,056"}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Election of two Class II directors to serve until the Company's 2029 Annual General Meeting of Shareholders at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 1A and Proposal No. 1B - Election of two Class II directors to serve until the Company’s 2029 Annual General Meeting of Shareholders and until their respective successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. Votes FOR Votes WITHHELD Broker Non-Votes Jonathan Violin, Ph.D. (Proposal No. 1A) 2,890,000 0 0 Susan Moran, M.D., MSCE (Proposal No. 1B) 21,401,136 136,056 2,403,515","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-040051","anchor_url":"https://secwatch.observer/filing/0001628280-26-040051#claim-9b7e850d3c34bc9636d45a9d51b77e475410c174","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/0001628280-26-040051-index.htm"},{"fact_type":"earnings_release","fact_key":"92423389a591e24ec4e300b099505c43a30378ea","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":"$0.70 and $19.63 per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$23.3 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-04-29","result_type":"reported_results","revenue_text":"$1.0 million"},"claim":"CRESCENT BIOPHARMA, INC. reported first quarter ended March 31, 2026 results: revenue $1.0 million, net income $23.3 million, EPS $0.70 and $19.63 per basic and diluted share.","evidence_excerpt":"cash equivalents were $189.2 million as of March 31, 2026 , which is anticipated to fund operations into 2028. 2 Revenue: Revenue for the three months ended March 31, 2026 was $1.0 million compared to no revenue in 2025. The revenue recognized in 2026 is the result of the $20.0 million upfront payment received from Kelun-Biotech pursuant to the license agreement","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-028386","anchor_url":"https://secwatch.observer/filing/0001628280-26-028386#claim-92423389a591e24ec4e300b099505c43a30378ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026028386/0001628280-26-028386-index.htm"},{"fact_type":"material_agreement","fact_key":"6f74a26dbbb130b118bca655a85a3f9b5d5bdd05","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-12-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional and other accredited investors","effective_date":"2025-12-04","item_codes_triggered":["1.01"],"value_text":"approximately $185.0 million"},"claim":"CRESCENT BIOPHARMA, INC. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at approximately $185.0 million (effective 2025-12-04).","evidence_excerpt":"On December 4, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and other accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). The closing of the Private Placement (the “Closing”) is expected to occur on December 8, 2025, subject to the satisfaction of customary closing conditions. Pursuant to the Purchase Agreement, the Purchasers agreed to purchase an aggregate of 13,795,685 ordinary shares with a par value of US$0.001 per share of the Company (the “Ordinary Shares”), at a purchase price per share of $13.41 (or, for certain investors in lieu of Ordinary Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Ordinary Shares (the “Pre-Funded Warrant Shares”), at a purchase price per underlying Pre-Funded Warrant Share of $13.409, which represents the per share purchase price of the Ordinary Shares less the $0.001 per shar","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-25-055221","anchor_url":"https://secwatch.observer/filing/0001628280-25-055221#claim-6f74a26dbbb130b118bca655a85a3f9b5d5bdd05","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/0001628280-25-055221-index.htm"},{"fact_type":"material_agreement","fact_key":"fe325c377d5a8bd003a9ef3e1baf8127ed758aa9","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-12-04T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment No. 1 to License Agreement","agreement_type":"license","counterparty":"Paragon Therapeutics, Inc.","effective_date":"2025-12-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"CRESCENT BIOPHARMA, INC. amended Amendment No. 1 to License Agreement with Paragon Therapeutics, Inc. (effective 2025-12-02).","evidence_excerpt":"On December 2, 2025, Crescent OpCo entered into Amendment No. 1 (the “Amendment”) to the License Agreement, dated April 28, 2025, by and between Crescent OpCo and Paragon Therapeutics, Inc., a Delaware corporation (the “Paragon License”), relating to CR-001.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-25-055221","anchor_url":"https://secwatch.observer/filing/0001628280-25-055221#claim-fe325c377d5a8bd003a9ef3e1baf8127ed758aa9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/0001628280-25-055221-index.htm"},{"fact_type":"material_agreement","fact_key":"7685f6cda7ad948f11e37dbbfb6bbc06eb702cd2","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-12-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"SKB105 License Agreement","agreement_type":"collaboration","counterparty":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","effective_date":"2025-12-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"CRESCENT BIOPHARMA, INC. entered into SKB105 License Agreement with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (effective 2025-12-02).","evidence_excerpt":"On December 2, 2025 (the “Effective Date”), Crescent OpCo and Kelun-Biotech entered into a License and Collaboration Agreement (the “SKB105 License Agreement”), under which Kelun-Biotech granted Crescent OpCo an exclusive license to research, develop, manufacture and commercialize SKB105, Kelun-Biotech’s proprietary integrin beta-6-directed antibody-drug conjugate, in all territories outside the SKB Territory.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-25-055221","anchor_url":"https://secwatch.observer/filing/0001628280-25-055221#claim-7685f6cda7ad948f11e37dbbfb6bbc06eb702cd2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/0001628280-25-055221-index.htm"},{"fact_type":"material_agreement","fact_key":"3f3695435558dc6cd677e17e93bdda91660d639d","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-12-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"CR-001 License Agreement","agreement_type":"license","counterparty":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","effective_date":"2025-12-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"CRESCENT BIOPHARMA, INC. entered into CR-001 License Agreement with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (effective 2025-12-02).","evidence_excerpt":"On December 2, 2025, Crescent OpCo and Kelun-Biotech entered into a License Agreement (the \"CR-001 License Agreement\") under which Crescent OpCo granted Kelun-Biotech an exclusive, royalty-bearing license to research, develop, manufacture and commercialize CR-001, Crescent’s proprietary bispecific antibody directed to VEGF and PD-1, in greater China (including mainland China, Hong Kong, Macau and Taiwan) (collectively, the “SKB Territory”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-25-055221","anchor_url":"https://secwatch.observer/filing/0001628280-25-055221#claim-3f3695435558dc6cd677e17e93bdda91660d639d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/0001628280-25-055221-index.htm"},{"fact_type":"equity_issuance","fact_key":"2ba8a93a33ffb51ccbf6dfc8408e5e05f839296d","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-12-04T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$13.409 per underlying Pre-Funded Warrant Share","effective_date":"2025-12-08","item_codes_triggered":["3.02"],"purchaser":"certain institutional and other accredited investors","security_type":"warrant","shares_text":"pre-funded warrants to purchase shares of Ordinary Shares"},"claim":"CRESCENT BIOPHARMA, INC. issued pre-funded warrants to purchase shares of Ordinary Shares of warrant to certain institutional and other accredited investors for $13.409 per underlying Pre-Funded Warrant Share.","evidence_excerpt":"pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Ordinary Shares (the “Pre-Funded Warrant Shares”), at a purchase price per underlying Pre-Funded Warrant Share of $13.409","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-25-055221","anchor_url":"https://secwatch.observer/filing/0001628280-25-055221#claim-2ba8a93a33ffb51ccbf6dfc8408e5e05f839296d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/0001628280-25-055221-index.htm"},{"fact_type":"equity_issuance","fact_key":"c8392d3a593e7efe388a8c26764400157c3d3097","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-12-04T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$13.41 per share","effective_date":"2025-12-08","item_codes_triggered":["3.02"],"purchaser":"certain institutional and other accredited investors","security_type":"common_stock","shares_text":"13,795,685 ordinary shares"},"claim":"CRESCENT BIOPHARMA, INC. issued 13,795,685 ordinary shares of common stock to certain institutional and other accredited investors for $13.41 per share.","evidence_excerpt":"Pursuant to the Purchase Agreement, the Purchasers agreed to purchase an aggregate of 13,795,685 ordinary shares with a par value of US$0.001 per share of the Company (the “Ordinary Shares”), at a purchase price per share of $13.41","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-25-055221","anchor_url":"https://secwatch.observer/filing/0001628280-25-055221#claim-c8392d3a593e7efe388a8c26764400157c3d3097","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/0001628280-25-055221-index.htm"},{"fact_type":"governance_change","fact_key":"fcc159ad811b214adcacc1a75d990873a24968a2","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"change_type":"shell_status","effective_date":"2025-06-16","item_codes_triggered":["5.06"],"summary_text":"Company ceased to be a shell company as a result of the Merger."},"claim":"CRESCENT BIOPHARMA, INC.: Company ceased to be a shell company as a result of the Merger (effective 2025-06-16).","evidence_excerpt":"As a result of the Merger, the Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-060714","anchor_url":"https://secwatch.observer/filing/0001104659-25-060714#claim-fcc159ad811b214adcacc1a75d990873a24968a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm"},{"fact_type":"governance_change","fact_key":"f458d5ce6137c7ee59030acb57b548126f82d5af","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"change_type":"code_of_ethics","effective_date":"2025-06-13","item_codes_triggered":["5.05"],"summary_text":"Adopted a new Code of Business Conduct and Ethics superseding the prior code."},"claim":"CRESCENT BIOPHARMA, INC.: Adopted a new Code of Business Conduct and Ethics superseding the prior code (effective 2025-06-13).","evidence_excerpt":"On June 13, 2025, in connection with the Closing, the Board adopted a new Code of Business Conduct and Ethics of the Company (the “ Code of Conduct ”), effective as of such date. The Code of Conduct supersedes the existing Code of Business Conduct and Ethics, as previously adopted by GlycoMimetics’ board of directors (the “ Existing Code of Conduct ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-060714","anchor_url":"https://secwatch.observer/filing/0001104659-25-060714#claim-f458d5ce6137c7ee59030acb57b548126f82d5af","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm"},{"fact_type":"governance_change","fact_key":"af5bc0234d46320bf2284638b00a5f32d67e6e25","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-16","item_codes_triggered":["5.03"],"summary_text":"Redomestication from Delaware to the Cayman Islands, including adoption of Cayman Islands Memorandum and Articles of Association."},"claim":"CRESCENT BIOPHARMA, INC.: Redomestication from Delaware to the Cayman Islands, including adoption of Cayman Islands Memorandum and Articles of Association (effective 2025-06-16).","evidence_excerpt":"Pursuant to the Plan of Conversion, to effect the Redomestication, the Company (i) filed a Certificate of Conversion with the Secretary of State of the State of Delaware (the “ Certificate of Conversion ”), with an effective time of 4:45 p.m., Eastern Daylight Time, on June 16, 2025, and (ii) filed the Cayman Articles, among other things, with the Cayman Islands Registrar of Companies, effective on June 16, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-060714","anchor_url":"https://secwatch.observer/filing/0001104659-25-060714#claim-af5bc0234d46320bf2284638b00a5f32d67e6e25","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm"},{"fact_type":"governance_change","fact_key":"be9e7b2af2cf41fdbf10b311147c78481fc2bd99","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-13","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Amendment to change company name."},"claim":"CRESCENT BIOPHARMA, INC.: Filed Certificate of Amendment to change company name (effective 2025-06-13).","evidence_excerpt":"To effect the Company Name Change, GlycoMimetics filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “ Name Change Certificate of Amendment ”), with an effective time of 8:50 a.m., Eastern Daylight Time, on June 13, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-060714","anchor_url":"https://secwatch.observer/filing/0001104659-25-060714#claim-be9e7b2af2cf41fdbf10b311147c78481fc2bd99","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm"},{"fact_type":"governance_change","fact_key":"edb37c16c6de93439759c3e0000b6d8420f998cb","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-13","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Amendment to increase authorized shares to 175,000,000."},"claim":"CRESCENT BIOPHARMA, INC.: Filed Certificate of Amendment to increase authorized shares to 175,000,000 (effective 2025-06-13).","evidence_excerpt":"To effect the Authorized Share Increase, GlycoMimetics filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “ Authorized Share Increase Certificate of Amendment ”), with an effective time of 8:47 a.m., Eastern Daylight Time, on June 13, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-060714","anchor_url":"https://secwatch.observer/filing/0001104659-25-060714#claim-edb37c16c6de93439759c3e0000b6d8420f998cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm"},{"fact_type":"governance_change","fact_key":"1aaac27515e6b7d5868767951d47dfd92c138df2","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-13","item_codes_triggered":["5.03"],"summary_text":"GlycoMimetics stockholders approved amendments to the certificate of incorporation to increase authorized shares from 150,000,000 to 175,000,000, effect a 1-for-100 reverse stock split, and redomesticate from Delaware to the Cayman Islands."},"claim":"CRESCENT BIOPHARMA, INC.: GlycoMimetics stockholders approved amendments to the certificate of incorporation to increase authorized shares from 150,000,000 to 175,000,000, effect a 1-for-100 reverse stock split, and redomesticate from Delaware to the Cayman Islands (effective 2025-06-13).","evidence_excerpt":"GlycoMimetics’ stockholders approved, among other matters, amendments to the amended and restated certificate of incorporation of GlycoMimetics to (i) increase the number of authorized shares of Company common stock from 150,000,000 shares to 175,000,000 (the “ Authorized Share Increase ”), (ii) effect the Reverse Stock Split and (iii) effect the redomestication of GlycoMimetics from the State of Delaware to the Cayman Islands by conversion and by way of continuation (the “ Redomestication ”) by means of a plan of conversion (the “ Plan of Conversion ”), in each case as described in the Proxy Statement/Prospectus.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-060714","anchor_url":"https://secwatch.observer/filing/0001104659-25-060714#claim-1aaac27515e6b7d5868767951d47dfd92c138df2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm"},{"fact_type":"auditor_change","fact_key":"e246a9b32efe9a8aa9a0086f69aeefee3d536537","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"PricewaterhouseCoopers LLP","disagreement_text":null,"effective_date":"2025-06-13","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"CRESCENT BIOPHARMA, INC. engaged PricewaterhouseCoopers LLP as its auditor.","evidence_excerpt":"On June 13, 2025, the Audit Committee appointed PwC as the independent registered public accounting firm of the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-060714","anchor_url":"https://secwatch.observer/filing/0001104659-25-060714#claim-e246a9b32efe9a8aa9a0086f69aeefee3d536537","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm"},{"fact_type":"auditor_change","fact_key":"3ed97be35fc72128e3173eb910dfcac14c243d79","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-06-18T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Ernst & Young LLP","disagreement_text":null,"effective_date":"2025-06-13","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"PricewaterhouseCoopers LLP"},"claim":"CRESCENT BIOPHARMA, INC. dismissed Ernst & Young LLP as its auditor.","evidence_excerpt":"On June 13, 2025, EY was dismissed as the independent registered public accounting firm of the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-060714","anchor_url":"https://secwatch.observer/filing/0001104659-25-060714#claim-3ed97be35fc72128e3173eb910dfcac14c243d79","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925060714/0001104659-25-060714-index.htm"},{"fact_type":"executive_change","fact_key":"fdfccd119c","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-21","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Scott Koenig resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-001517","anchor_url":"https://secwatch.observer/filing/0001558370-25-001517#claim-fdfccd119c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm"},{"fact_type":"executive_change","fact_key":"226bee0065","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-21","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rachel King resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-001517","anchor_url":"https://secwatch.observer/filing/0001558370-25-001517#claim-226bee0065","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm"},{"fact_type":"executive_change","fact_key":"55d17dab71","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-21","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Scott Jackson resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-001517","anchor_url":"https://secwatch.observer/filing/0001558370-25-001517#claim-55d17dab71","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm"},{"fact_type":"executive_change","fact_key":"3e0859b4b4","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-21","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Mark Goldberg resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-001517","anchor_url":"https://secwatch.observer/filing/0001558370-25-001517#claim-3e0859b4b4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm"},{"fact_type":"executive_change","fact_key":"816677156a","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"ceased employment","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-21","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Brian Hahn departed as Chief Financial Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-001517","anchor_url":"https://secwatch.observer/filing/0001558370-25-001517#claim-816677156a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm"},{"fact_type":"executive_change","fact_key":"290de6af05","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-21","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Harout Semerjian resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-001517","anchor_url":"https://secwatch.observer/filing/0001558370-25-001517#claim-290de6af05","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm"},{"fact_type":"executive_change","fact_key":"860c9512d0","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-25T23:59:59+00:00","payload":{"action":"ceased employment","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-21","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Harout Semerjian departed as Chief Executive Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-001517","anchor_url":"https://secwatch.observer/filing/0001558370-25-001517#claim-860c9512d0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm"},{"fact_type":"executive_change","fact_key":"519a68de04","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-01-31T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Brian Hahn resigned as Chief Financial Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"Mr. Brian Hahn, the Company’s Chief Financial Officer, notified the Company’s board of directors of his intent to cease his respective employment with the Company no later than March 31, 2025.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001558370-25-000576","anchor_url":"https://secwatch.observer/filing/0001558370-25-000576#claim-519a68de04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025000576/0001558370-25-000576-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"0a632316beb90ba2ab05db5253e6474819988a86","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-12-26T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-06-16","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-12-19","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"CRESCENT BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"December 19, 2024, GlycoMimetics, Inc. (the “ Company ”) received a notice (the “ Extension Notice ”) from the Listing Qualifications Department of the Nasdaq Stock Market (“ Nasdaq ”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until June 16, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). In connection with the Extension Notice, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-016472","anchor_url":"https://secwatch.observer/filing/0001558370-24-016472#claim-0a632316beb90ba2ab05db5253e6474819988a86","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024016472/0001558370-24-016472-index.htm"},{"fact_type":"restructuring_charge","fact_key":"e6a05755c1c922c28abf7eb8cb9420016d729578","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-07-30T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $3.6 million","effective_date":"2024-07-24","event_type":"restructuring","headcount_text":"reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount","item_codes_triggered":["2.05"]},"claim":"CRESCENT BIOPHARMA, INC. announced a restructuring with charges of approximately $3.6 million (reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount).","evidence_excerpt":"in connection with the streamlined operating plan approved by the Board, on July 24, 2024, the authorized officers of the Company committed the Company to a corporate restructuring that includes a reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount. The Company expects to substantially complete the reduction by July 31, 2024. The Company anticipates recognizing approximately $3.6 million in total charges in connection with the headcount reduction","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-010370","anchor_url":"https://secwatch.observer/filing/0001558370-24-010370#claim-e6a05755c1c922c28abf7eb8cb9420016d729578","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm"},{"fact_type":"executive_change","fact_key":"f6b3b07dab","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-07-30T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-31","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. Edwin Rock departed as Chief Medical Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"the employment of Dr. Edwin Rock, the Company’s Chief Medical Officer, will end on July 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-010370","anchor_url":"https://secwatch.observer/filing/0001558370-24-010370#claim-f6b3b07dab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm"},{"fact_type":"earnings_release","fact_key":"771dbb4e3ed78ea50d2af0b7d849be415e34490a","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter of 2024","report_date":"2024-05-06","result_type":"preliminary_results","revenue_text":null},"claim":"CRESCENT BIOPHARMA, INC. reported preliminary financial results for first quarter of 2024.","evidence_excerpt":"On May 6, 2024, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing, in addition to the information described in Item 7.01 below, its financial results for the first quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-006793","anchor_url":"https://secwatch.observer/filing/0001558370-24-006793#claim-771dbb4e3ed78ea50d2af0b7d849be415e34490a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/0001558370-24-006793-index.htm"},{"fact_type":"governance_change","fact_key":"333aa435f7970ee3d27d41177263b80e7bfef01b","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-05-01","item_codes_triggered":["5.03"],"summary_text":"Amendment to certificate of incorporation to add officer exculpation provision as permitted by Delaware law."},"claim":"CRESCENT BIOPHARMA, INC.: Amendment to certificate of incorporation to add officer exculpation provision as permitted by Delaware law (effective 2024-05-01).","evidence_excerpt":"At the 2024 Annual Meeting of Stockholders held on May 1, 2024 (the “ Annual Meeting ”), the stockholders of GlycoMimetics, Inc. (the “ Company ”) approved (i) an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Restated Certificate ”) to increase the authorized number of shares of the Company’s common stock from 100,000,000 to 150,000,000 shares and (ii) an amendment to the Restated Certificate to include a provision eliminating or limiting monetary liability for specified corporate officers for breach of fiduciary duty in certain actions as permitted by the General Corporation Law of the State of Delaware.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-006459","anchor_url":"https://secwatch.observer/filing/0001558370-24-006459#claim-333aa435f7970ee3d27d41177263b80e7bfef01b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm"},{"fact_type":"governance_change","fact_key":"c6f71eceda223d4ab9b2ea8d1fc68c6883939011","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-05-01","item_codes_triggered":["5.03"],"summary_text":"Amendment to increase authorized shares of common stock from 100,000,000 to 150,000,000 shares."},"claim":"CRESCENT BIOPHARMA, INC.: Amendment to increase authorized shares of common stock from 100,000,000 to 150,000,000 shares (effective 2024-05-01).","evidence_excerpt":"At the 2024 Annual Meeting of Stockholders held on May 1, 2024 (the “ Annual Meeting ”), the stockholders of GlycoMimetics, Inc. (the “ Company ”) approved (i) an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Restated Certificate ”) to increase the authorized number of shares of the Company’s common stock from 100,000,000 to 150,000,000 shares and (ii) an amendment to the Restated Certificate to include a provision eliminating or limiting monetary liability for specified corporate officers for breach of fiduciary duty in certain actions as permitted by the General Corporation Law of the State of Delaware.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-006459","anchor_url":"https://secwatch.observer/filing/0001558370-24-006459#claim-c6f71eceda223d4ab9b2ea8d1fc68c6883939011","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm"},{"fact_type":"shareholder_vote","fact_key":"591dc3f3622a82bb66b0afb5f8a65617756170a0","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-01","outcome":"passed","proposal_text":"Amend Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.","proposal_type":"charter_amendment","results":[{"broker_non_votes":"13,231,353","subject":null,"votes_abstain":"31,322","votes_against":"1,045,748","votes_for":"36,172,684","votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Amend Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. at the 2024-05-01 meeting.","evidence_excerpt":"Proposal No. 5: Stockholders approved an amendment to the Restated Certificate to reflect new Delaware law provisions regarding officer exculpation. The votes were cast as follows: ​ 6,172,8 Votes For Votes Against Abstentions Amend Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. 36,172,684 ​ 1,045,748 ​ 31,322 ​ Broker Non-Votes: 13,231,353 ​","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-006459","anchor_url":"https://secwatch.observer/filing/0001558370-24-006459#claim-591dc3f3622a82bb66b0afb5f8a65617756170a0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6921524fd2341ccd4ec078bfb5da1e00aea0e782","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-01","outcome":"passed","proposal_text":"Amend Certificate of Incorporation to increase authorized shares of common stock from 100,000,000 to 150,000,000.","proposal_type":"charter_amendment","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"134,273","votes_against":"1,014,592","votes_for":"49,332,242","votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Amend Certificate of Incorporation to increase authorized shares of common stock from 100,000,000 to 150,000,000. at the 2024-05-01 meeting.","evidence_excerpt":"Proposal No. 4: Stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Restated Certificate ”) to increase the authorized number of shares of common stock from 100,000,000 shares to 150,000,000 shares. The votes were cast as follows: ​ Votes For Votes Against Abstentions Amend Certificate of Incorporation to increase authorized shares of common stock from 100,000,000 to 150,000,000. 49,332,242 ​ 1,014,592 ​ 134,273 ​ Broker Non-Votes: 0 ​","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-006459","anchor_url":"https://secwatch.observer/filing/0001558370-24-006459#claim-6921524fd2341ccd4ec078bfb5da1e00aea0e782","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm"},{"fact_type":"shareholder_vote","fact_key":"415e8d309849be1aa2c43f13590e6cf873d23227","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-01","outcome":"passed","proposal_text":"Approval, on an advisory basis, of the executive compensation of the named executive officers.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"13,231,353","subject":null,"votes_abstain":"75,670","votes_against":"1,881,276","votes_for":"35,292,808","votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Approval, on an advisory basis, of the executive compensation of the named executive officers. at the 2024-05-01 meeting.","evidence_excerpt":"Proposal No. 3: Stockholders approved, on an advisory basis, the executive compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The votes were cast as follows: ​ 5,2 Votes For Votes Against Abstentions Approval, on an advisory basis, of the executive compensation of the named executive officers. 35,292,808 ​ 1,881,276 ​ 75,670 ​ Broker Non-Votes: 13,231,353 2 ​ ​","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-006459","anchor_url":"https://secwatch.observer/filing/0001558370-24-006459#claim-415e8d309849be1aa2c43f13590e6cf873d23227","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm"},{"fact_type":"shareholder_vote","fact_key":"60406f88da26ca1ab7892bb4b3753485bc969a20","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-01","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"121,215","votes_against":"40,448","votes_for":"50,319,444","votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. at the 2024-05-01 meeting.","evidence_excerpt":"Proposal No. 2 :  Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: ​ Votes For Votes Against Abstentions Ratification of appointment of Ernst & Young LLP 50,319,444 ​ 40,448 ​ 121,215 ​ ​ ​","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-006459","anchor_url":"https://secwatch.observer/filing/0001558370-24-006459#claim-60406f88da26ca1ab7892bb4b3753485bc969a20","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm"},{"fact_type":"shareholder_vote","fact_key":"be1e3299fede9218a7aac19b6d79dbc8828e18e3","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-01","outcome":"passed","proposal_text":"Stockholders elected two nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified.","proposal_type":"director_election","results":[{"broker_non_votes":"13,231,353","subject":"Daniel Junius","votes_abstain":null,"votes_against":null,"votes_for":"34,583,868","votes_withheld":"2,665,886"},{"broker_non_votes":"13,231,353","subject":"Rachel King","votes_abstain":null,"votes_against":null,"votes_for":"37,007,330","votes_withheld":"242,424"}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Stockholders elected two nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2024-05-01 meeting.","evidence_excerpt":"Proposal No. 1 :  Stockholders elected two nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: ​ Name Votes For Votes Withheld Daniel Junius 34,583,868 ​ 2,665,886 Rachel King ​ 37,007,330 ​ 242,424 ​ ​ Broker Non-Votes: 13,231,353 ​","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-006459","anchor_url":"https://secwatch.observer/filing/0001558370-24-006459#claim-be1e3299fede9218a7aac19b6d79dbc8828e18e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm"},{"fact_type":"earnings_release","fact_key":"75b4f89aefc6e108aca415c1496074c232be7912","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-03-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2023","report_date":"2024-03-27","result_type":"reported_results","revenue_text":null},"claim":"CRESCENT BIOPHARMA, INC. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-004015","anchor_url":"https://secwatch.observer/filing/0001558370-24-004015#claim-75b4f89aefc6e108aca415c1496074c232be7912","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024004015/0001558370-24-004015-index.htm"},{"fact_type":"material_agreement","fact_key":"036eb6212b6acc8cb6bf10748511a377a187e9ca","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2024-01-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Project Agreement","agreement_type":"supply","counterparty":"Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific","effective_date":"2024-01-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"CRESCENT BIOPHARMA, INC. entered into Project Agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (effective 2024-01-02).","evidence_excerpt":"On January 2, 2024, GlycoMimetics, Inc. (the “ Company ”) entered into a project agreement (the “ Project Agreement ”) with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (“ Patheon ”), pursuant to which Patheon will manufacture and supply the Company with its drug candidate, uproleselan, for commercial sale should the Company receive marketing approval from the U.S. Food and Drug Administration.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-000013","anchor_url":"https://secwatch.observer/filing/0001558370-24-000013#claim-036eb6212b6acc8cb6bf10748511a377a187e9ca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837024000013/0001558370-24-000013-index.htm"},{"fact_type":"earnings_release","fact_key":"0eaf3192dc8da14f2a2612d202826927cda3d9bb","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-11-03T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-03","result_type":"reported_results","revenue_text":null},"claim":"CRESCENT BIOPHARMA, INC. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-017507","anchor_url":"https://secwatch.observer/filing/0001558370-23-017507#claim-0eaf3192dc8da14f2a2612d202826927cda3d9bb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023017507/0001558370-23-017507-index.htm"},{"fact_type":"earnings_release","fact_key":"9e9bef874eb3de48c24dbde2baeb8e905b8d613c","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-08-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the second quarter ended June 30, 2023","report_date":"2023-08-02","result_type":"reported_results","revenue_text":null},"claim":"CRESCENT BIOPHARMA, INC. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 2, 2023, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-012816","anchor_url":"https://secwatch.observer/filing/0001558370-23-012816#claim-9e9bef874eb3de48c24dbde2baeb8e905b8d613c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023012816/0001558370-23-012816-index.htm"},{"fact_type":"shareholder_vote","fact_key":"18bdc45736e0e4979fd4c5dba24c9242f8c3c141","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-19","outcome":"passed","proposal_text":"To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"14,198,293","subject":null,"votes_abstain":"112,283","votes_against":"435,570","votes_for":"36,116,823","votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials. at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 3: To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials. The votes were cast as follows: ​ Votes For Votes Against Abstained Approved, on an advisory basis, the executive compensation. 36,116,823 ​ 435,570 ​ 112,283 ​ Broker Non-Votes: 14,198,293.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001558370-23-010301","anchor_url":"https://secwatch.observer/filing/0001558370-23-010301#claim-18bdc45736e0e4979fd4c5dba24c9242f8c3c141","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c26aed0e386b55a970b434ac7d72623eb8b7253f","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-19","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"51,807","votes_against":"474,059","votes_for":"50,337,103","votes_withheld":null}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 2 :  Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: ​ Votes For Votes Against Abstained Ratification of appointment of Ernst & Young 50,337,103 ​ 474,059 ​ 51,807","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001558370-23-010301","anchor_url":"https://secwatch.observer/filing/0001558370-23-010301#claim-c26aed0e386b55a970b434ac7d72623eb8b7253f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cb624e21b97e5c61b8bb6a2470d0806d492ea5f4","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-05-22T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-19","outcome":"passed","proposal_text":"Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified.","proposal_type":"director_election","results":[{"broker_non_votes":"14,198,293","subject":"Patricia Andrews","votes_abstain":null,"votes_against":null,"votes_for":"36,190,925","votes_withheld":"473,751"},{"broker_non_votes":"14,198,293","subject":"Mark Goldberg, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"32,642,583","votes_withheld":"4,022,093"},{"broker_non_votes":"14,198,293","subject":"Timothy Pearson","votes_abstain":null,"votes_against":null,"votes_for":"36,279,306","votes_withheld":"385,370"}]},"claim":"CRESCENT BIOPHARMA, INC. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 1 :  Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: ​ Name Votes For Votes Withheld Patricia Andrews 36,190,925 ​ 473,751 Mark Goldberg, M.D. ​ 32,642,583 ​ 4,022,093 Timothy Pearson ​ 36,279,306 ​ 385,370 ​ ​ Broker Non-Votes: 14,198,293. ​ All nominees were elected.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001558370-23-010301","anchor_url":"https://secwatch.observer/filing/0001558370-23-010301#claim-cb624e21b97e5c61b8bb6a2470d0806d492ea5f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm"},{"fact_type":"earnings_release","fact_key":"5637ecb762dd4acc9e1922bee7701026a23b71cf","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-05-03T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2023","report_date":"2023-05-03","result_type":"reported_results","revenue_text":null},"claim":"CRESCENT BIOPHARMA, INC. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 3, 2023, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-007746","anchor_url":"https://secwatch.observer/filing/0001558370-23-007746#claim-5637ecb762dd4acc9e1922bee7701026a23b71cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/0001558370-23-007746-index.htm"},{"fact_type":"material_agreement","fact_key":"d6dde62118133b348aab1d37e822762feff1351e","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-04-21T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Third Amendment to Lease","agreement_type":"lease","counterparty":"ARE-Maryland No. 45, LLC","effective_date":"2023-04-19","item_codes_triggered":["1.01"],"value_text":"Lease amended to terminate for approximately 12,000 sq ft on October 31, 2023 and extend remaining 3"},"claim":"CRESCENT BIOPHARMA, INC. amended Third Amendment to Lease with ARE-Maryland No. 45, LLC valued at Lease amended to terminate for approximately 12,000 sq ft on October 31, 2023 and extend remaining 3 (effective 2023-04-19).","evidence_excerpt":"On April 19, 2023, GlycoMimetics, Inc. (the “ Company ”) entered into a Third Amendment to Lease (the “ Lease Amendment ”) with ARE-Maryland No. 45, LLC, a Delaware limited liability company (the “ Landlord ”). The Lease Amendment amends the Lease Agreement, dated July 23, 2014 and as subsequently amended (as so amended, the “ Lease ”), by and between the Company and BMR-Medical Center Drive LLC, the original landlord that subsequently conveyed to Landlord the premises subject to the Lease. Pursuant to the Lease, the Company leases approximately 42,000 rentable square feet of space in Rockville, Maryland (the “ Premises ”) with a term that expires on October 31, 2023.  Pursuant to the Lease Amendment, the Company and the Landlord have agreed that the Lease will terminate on October 31, 2023 with respect to approximately 12,000 square feet of the Premises, and that the Lease for the remaining approximately 30,000 square feet of the Premises will be extended until January 31, 2025, unles","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-006434","anchor_url":"https://secwatch.observer/filing/0001558370-23-006434#claim-d6dde62118133b348aab1d37e822762feff1351e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023006434/0001558370-23-006434-index.htm"},{"fact_type":"earnings_release","fact_key":"8c33ed8121b52599a893d643fcfab39f69a2efae","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-03-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter and year ended December 31, 2022","report_date":"2023-03-29","result_type":"reported_results","revenue_text":null},"claim":"CRESCENT BIOPHARMA, INC. reported financial results for quarter and year ended December 31, 2022.","evidence_excerpt":"GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-004866","anchor_url":"https://secwatch.observer/filing/0001558370-23-004866#claim-8c33ed8121b52599a893d643fcfab39f69a2efae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/0001558370-23-004866-index.htm"},{"fact_type":"executive_change","fact_key":"0d0e1badab","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"action":"agreed that his employment will end","action_category":"departure","departure_tone":"routine","effective_date":"2023-03-31","interim":false,"role":"Senior Vice President of Research and Chief Scientific Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"John Magnani departed as Senior Vice President of Research and Chief Scientific Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"On February 21, 2023, GlycoMimetics, Inc. (the “ Company ”) and Dr. John Magnani, the Company’s Senior Vice President of Research and Chief Scientific Officer, entered into an agreement (the “ Transition Agreement ”) pursuant to which the Company and Dr. Magnani have agreed that his employment with the Company will end on March 31, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-001631","anchor_url":"https://secwatch.observer/filing/0001558370-23-001631#claim-0d0e1badab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/0001558370-23-001631-index.htm"},{"fact_type":"earnings_release","fact_key":"693d8c948d6a6dfefb98375b7f0dbe3653baedfd","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2022-11-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended September 30, 2022","report_date":"2022-11-09","result_type":"reported_results","revenue_text":"There was no revenue recognized during the three months ended September 30, 2022"},"claim":"CRESCENT BIOPHARMA, INC. reported third quarter ended September 30, 2022 results: revenue There was no revenue recognized during the three months ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001558370-22-017028","anchor_url":"https://secwatch.observer/filing/0001558370-22-017028#claim-693d8c948d6a6dfefb98375b7f0dbe3653baedfd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/0001558370-22-017028-index.htm"},{"fact_type":"executive_change","fact_key":"3e54e8b47a","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2021-08-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-08-06","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Harout Semerjian was appointed as President and Chief Executive Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"On August 2, 2021, the Board appointed Harout Semerjian as the Company’s President and Chief Executive Officer, effective as of August 6, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-21-010404","anchor_url":"https://secwatch.observer/filing/0001558370-21-010404#claim-3e54e8b47a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837021010404/0001558370-21-010404-index.htm"},{"fact_type":"executive_change","fact_key":"e34605a0d5","cik":1253689,"ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2021-08-05T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2021-08-06","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Harout Semerjian","successor_named":true},"claim":"Rachel K. King retired as President and Chief Executive Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"On July 30, 2021, Rachel K. King, President and Chief Executive Officer of the Company, notified the Board of Directors of the Company (the “ Board ”) of her decision to retire from those positions, effective as of August 6, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-21-010404","anchor_url":"https://secwatch.observer/filing/0001558370-21-010404#claim-e34605a0d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837021010404/0001558370-21-010404-index.htm"}]}